Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital ExperienceOncology Published on 2020-11-202022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] age associations Cancer Cerebrovascular disease co-morbidities co-morbidity Cohort contribute country COVID-19 COVID-19 diagnosis COVID-19 pandemic experience Hematological malignancy history hospital increased mortality Increasing independent independent risk factor influence Laboratory London Mortality pandemic pathophysiology Patient Patients with cancer predicted Randomly Result risk Risk factors SACT SARS-COV-2 infection selected solid cancer solid cancers South Asian systemic systemic anti-cancer therapy Tertiary Treatment were excluded [DOI] 10.3389/fonc.2020.595804 PMC 바로가기 [Article Type] Oncology
Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 InfectionPerspective Published on 2020-11-162022-10-31 Journal: Cancers [Category] COVID-19, [키워드] adverse outcome anti-cancer treatment cancer patient clinicians and researcher Consequences coronavirus Course COVID-19 COVID-19 patients cytotoxic T lymphocyte antigen-4 evaluate the effect Evidence exacerbated Hematological malignancies Immune checkpoint inhibitor Immune checkpoint inhibitors immune response immunosuppressive therapies increased risk Infection infection with SARS-CoV-2 information knowledge less management morbidity and mortality Mortality pandemic Patient patients with COVID-19 programmed cell death protein promote receiving risk SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection Severe infection Side effect simple solid cancer T cell Topic treated Treatment turn viral infection with COVID-19 [DOI] 10.3390/cancers12113383 PMC 바로가기 [Article Type] Perspective
Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in GermanyOriginal Research Published on 2020-09-152022-10-31 Journal: Cancer Medicine [Category] COVID-19, SARS, [키워드] association Cancer cancer diagnosis Cancer management center Clinical characteristics Clinical improvement Cohort cohort of patient cohort study Comprehensive Diagnosis died eight Epidemiology epidemiology and prevention event events Fatality rate Germany hematological hematological cancer Hematological malignancy Hospitalization Hospitalized hotspot IL‐6 influences on investigated Major malignancy Mortality multivariate Cox regression observation period observé Occurrence outcome Patient performed Presence Probability Result retrospective severe disease course significantly single center solid cancer solid tumor survival university viral infection Viral pneumonia [DOI] 10.1002/cam4.3460 PMC 바로가기 [Article Type] Original Research
Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission Research Published on 2020-07-202022-10-05 Journal: Leukemia [Category] SARS, 치료기술, 치료법, [키워드] 95% confidence interval acute respiratory syndrome Cancer Complete coronavirus disease Coronavirus-2 COVID-19 hazard ratio help hematological cancers In-hospital death increase independent risk factor Infection outcome predict risk SARS-CoV-2 Seven solid cancer subject with COVID-19 Wuhan, China [DOI] 10.1038/s41375-020-0986-7 [Article Type] Research
COVID-19 in persons with haematological cancers Research Published on 2020-04-242022-10-05 Journal: Leukemia [Category] SARS, 치료법, [키워드] baseline cancers Care Case fatality rate caused cohort study conducted confidence coronavirus COVID-19 death Fatality rate had more Haematological cancer Health hospitalised identify interval Isolation no significant difference outcome outcomes pandemic Protective risk factor SARS-CoV-2 severe COVID-19 severe disease solid cancer subject Surveillance with COVID-19 Wuhan, China [DOI] 10.1038/s41375-020-0836-7 [Article Type] Research